Michael Friedlander

Michael Friedlander

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Michael Friedlander

Prince of Wales Hospital and Royal Hospital for Women Randwick, Sydney, Australia

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2018 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
KMKathleen Moore
Kathleen Moore
NCNicoletta Colombo
Nicoletta Colombo
GSGiovanni Scambia
Giovanni Scambia
BKByoung-Gie Kim
Byoung-Gie Kim
AOAna Oaknin
Ana Oaknin
PDPaul DiSilvestro
Paul DiSilvestro
Most women with newly diagnosed advanced ovarian cancer have a relapse within 3 years after standard treatment with surgery and platinum-based chemotherapy. The benefit of the oral poly(adenosine diphosphate–ribose) polymerase inhibitor olaparib in relapsed disease has been well established, but the benefit of olaparib as maintenance therapy in newly diagnosed disease is uncertain. We conducted an international, randomized, double-blind, phase 3 trial to evaluate the efficacy of olaparib as maintenance therapy in patients with newly diagnosed advanced (International Federation of Gynecology and Obstetrics stage III or IV) high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian-tube cancer (or a combination thereof) with a mutation in BRCA1, BRCA2, or both (BRCA1/2) who had a complete or partial clinical response after platinum-based chemotherapy. The patients were randomly assigned, in a 2:1 ratio, to receive olaparib tablets (300 mg twice daily) or placebo. The primary end point was progression-free survival. Of the 391 patients who underwent randomization, 260 were assigned to receive olaparib and 131 to receive placebo. A total of 388 patients had a centrally confirmed germline BRCA1/2 mutation, and 2 patients had a centrally confirmed somatic BRCA1/2 mutation. After a median follow-up of 41 months, the risk of disease progression or death was 70% lower with olaparib than with placebo (Kaplan–Meier estimate of the rate of freedom from disease progression and from death at 3 years, 60% vs. 27%; hazard ratio for disease progression or death, 0.30; 95% confidence interval, 0.23 to 0.41; P<0.001). Adverse events were consistent with the known toxic effects of olaparib. The use of maintenance therapy with olaparib provided a substantial benefit with regard to progression-free survival among women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, with a 70% lower risk of disease progression or death with olaparib than with placebo. (Funded by AstraZeneca and Merck; SOLO1 ClinicalTrials.gov number, NCT01844986.)

12 April 2012 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
JLJonathan Ledermann
Jonathan Ledermann
PHPhilipp Harter
Philipp Harter
CGCharlie Gourley
Charlie Gourley
MFMichael Friedlander
Michael Friedlander
IVIgnace Vergote
Ignace Vergote
UMUrsula Matulonis
Ursula Matulonis
Olaparib (AZD2281) is an oral poly(adenosine diphosphate [ADP]–ribose) polymerase inhibitor that has shown antitumor activity in patients with high-grade serous ovarian cancer with or without BRCA1 or BRCA2 germline mutations. We conducted a randomized, double-blind, placebo-controlled, phase 2 study to evaluate maintenance treatment with olaparib in patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer who had received two or more platinum-based regimens and had had a partial or complete response to their most recent platinum-based regimen. Patients were randomly assigned to receive olaparib, at a dose of 400 mg twice daily, or placebo. The primary end point was progression-free survival according to the Response Evaluation Criteria in Solid Tumors guidelines. Of 265 patients who underwent randomization, 136 were assigned to the olaparib group and 129 to the placebo group. Progression-free survival was significantly longer with olaparib than with placebo (median, 8.4 months vs. 4.8 months from randomization on completion of chemotherapy; hazard ratio for progression or death, 0.35; 95% confidence interval [CI], 0.25 to 0.49; P<0.001). Subgroup analyses of progression-free survival showed that, regardless of subgroup, patients in the olaparib group had a lower risk of progression. Adverse events more commonly reported in the olaparib group than in the placebo group (by more than 10% of patients) were nausea (68% vs. 35%), fatigue (49% vs. 38%), vomiting (32% vs. 14%), and anemia (17% vs. 5%); the majority of adverse events were grade 1 or 2. An interim analysis of overall survival (38% maturity, meaning that 38% of the patients had died) showed no significant difference between groups (hazard ratio with olaparib, 0.94; 95% CI, 0.63 to 1.39; P=0.75). Olaparib as maintenance treatment significantly improved progression-free survival among patients with platinum-sensitive, relapsed, high-grade serous ovarian cancer. Interim analysis showed no overall survival benefit. The toxicity profile of olaparib in this population was consistent with that in previous studies. (Funded by AstraZeneca; ClinicalTrials.gov number, NCT00753545.)

1 October 2017 in The Lancet
Verified
Journal Article
Closed access
RCRobert Robert Coleman
Robert Robert Coleman
AOAmit Oza
Amit Oza
DLDomenica Lorusso
Domenica Lorusso
CACarol Aghajanian
Carol Aghajanian
AOAna Oaknin
Ana Oaknin
MVM Vulfovich
M Vulfovich

1 September 2017 in The Lancet Oncology
Verified
Journal Article
Closed access
EPEric Pujade-Lauraine
Eric Pujade-Lauraine
JLJonathan A Ledermann
Jonathan A Ledermann
FSFrédéric Selle
Frédéric Selle
VGVal Gebski
Val Gebski
RPRichard T Penson
Richard T Penson
IVIgnace Vergote
Ignace Vergote

20 January 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BKBella Kaufman
Bella Kaufman
RSRonnie Shapira-Frommer
Ronnie Shapira-Frommer
RSRita K. Schmutzler
Rita K. Schmutzler
MAM. William Audeh
M. William Audeh
MFMichael Friedlander
Michael Friedlander
SDSusan M. Domchek
Susan M. Domchek
Purpose: Olaparib is an oral poly (ADP-ribose) polymerase inhibitor with activity in germline BRCA1 and BRCA2 (BRCA1/2) –associated breast and ovarian cancers. We evaluated the efficacy and safety of olaparib in a spectrum of BRCA1/2-associated cancers. Patients and Methods: This multicenter phase II study enrolled individuals with a germline BRCA1/2 mutation and recurrent cancer. Eligibility included ovarian cancer resistant to prior platinum; breast cancer with ≥ three chemotherapy regimens for metastatic disease; pancreatic cancer with prior gemcitabine treatment; or prostate cancer with progression on hormonal and one systemic therapy. Olaparib was administered at 400 mg twice per day. The primary efficacy end point was tumor response rate. Results: A total of 298 patients received treatment and were evaluable. The tumor response rate was 26.2% (78 of 298; 95% CI, 21.3 to 31.6) overall and 31.1% (60 of 193; 95% CI, 24.6 to 38.1), 12.9% (eight of 62; 95% CI, 5.7 to 23.9), 21.7% (five of 23; 95% CI, 7.5 to 43.7), and 50.0% (four of eight; 95% CI, 15.7 to 84.3) in ovarian, breast, pancreatic, and prostate cancers, respectively. Stable disease ≥ 8 weeks was observed in 42% of patients (95% CI, 36.0 to 47.4), including 40% (95% CI, 33.4 to 47.7), 47% (95% CI, 34.0 to 59.9), 35% (95% CI, 16.4 to 57.3), and 25% (95% CI, 3.2 to 65.1) of those with ovarian, breast, pancreatic, or prostate cancer, respectively. The most common adverse events (AEs) were fatigue, nausea, and vomiting. Grade ≥ 3 AEs were reported for 54% of patients; anemia was the most common (17%). Conclusion: Responses to olaparib were observed across different tumor types associated with germline BRCA1/2 mutations. Olaparib warrants further investigation in confirmatory studies.

27 May 2015 in Nature
Verified
Journal Article
Closed access
PDF file
APAnn-Marie Patch
Ann-Marie Patch
ECElizabeth L Christie
Elizabeth L Christie
DEDariush Etemadmoghadam
Dariush Etemadmoghadam
DGDale W. Garsed
Dale W. Garsed
JGJoshy George
Joshy George
DBDavid D. L. Bowtell
David D. L. Bowtell